Peginterferon alfa-2b (PEG-Intron, Pegasys)

JCODE: J3490

SELF ADMINISTRATION  

Oral ribavirin is covered under the Pharmacy Benefit

All of the following must be met:
  • Diagnosis of Chronic Hepatitis C
  • Persistently elevated LFT’s (> 6 months)
  • Positive HCV RNA titer
  • Obtain Genotype (1 or 2 or 3)

Approve for combination therapy:

(Peg Intron/Pegasys + ribavirin)*

  • Naïve: No history of interferon alfa treatment
  • Relapser: Prior treatment with interferon alfa for 6 months and patient has a complete biochemical remission and then a relapse
  • Non-Responders: ALT remains abnormal & serum HCV RNA remains detectable after three months of Intron A therapy

Approve for monotherapy only if: 

  • Contraindication to ribavirin OR
  • Failure Due to ribavirin Adverse Effects
  • Interferon alfa + ribavirin relapsers (if completed course of therapy)
  • Allow another full course of Pegasys + Ribavirin + boceprevir/telaprevir

* Highest response rates seen with combination therapy in Hepatitis C Patients

Patients for whom peginterferon alfa-2b therapy is not indicated include

  • Patients who do not have persistently elevated LFT’s (> 6 months)
  • Patients with decompensated cirrhosis (ascites, GI bleed, encephalopathy)
  • Patients w/o significant inflammation or fibrosis on liver biopsy (if biopsy available)
  • Hepatitis C Prophylaxis Post-Liver Transplant
  • Patients who have a documented relapse of Hepatitis C post-transplant may be eligible for treatment for up to 1 year in duration. Refer PA requests to Medical Director
  • Other Viral Conditions: Acute Hepatitis B or C, Epstein-Barr Virus, cytomegalovirus, Hepatitis D or E
  • oral ribavirin dosing higher than 1,200MG per day

Pegasys/Pegintron + Ribavirin Non-Responders

  • If completed course of therapy and no response is seen: Needs medical director review. There is no literature to support continued use of combination therapy in non-responders

Dosing:

Administer SQ once weekly. The dose should be given on the same day of each week

Dose Reduction:

  • If a serious adverse reaction develops, DC or the dosage of PEG-Intron to 1/2 the starting dosage until the adverse event stops or decreases in severity. If intolerance is persistent or reoccurs despite dosage adjustment, DC treatment with PEG-Intron
  • In the event of neutropenia and thrombocytopenia, the following dose modifications are recommended by the manufacturer:
    • ANC < 750 cells/mm3: dose as above
    • ANC < 500 cells/mm3: permanent DC
    • Platelet count <80 x 109/L: dose as above
    • Platelet count <50 x 109/L: permanent DC
  • In anemia associated with Peginterferon/ribavirin Therapy
    • Erythropoietin 40,000 U once weekly

Monitor:

  • Baseline Labs: CBC, LFTs, HCV RNA PCR
  • Ongoing: CBC, LFTS, HCV RNA PCR q mo. oral ribavirin dosing: Up to 1,200 mg/day are approvable

***This includes weight-based dosing***

Peg Intron/Pegasys + ribavirin:
  • Assess whether patient is genotype 1 or genotype 2 or 3
  • Genotype 1, 4, 6 or 7 or any genotype and HIV co-infection: Approve for 12 weeks and obtain viral load to assess response (2 log10 drop or negative HCV RNA) Approve for 36 additional weeks once response is documented
  • In Genotype 1, 4 , 6 or 7 or any genotype and HIV co-infection patients with no response at 12 weeks, medical director will discuss discontinuing therapy
  • Genotype 1, 4, 6, 7 or any genotype and HIV co-infection with a detectable viral load and a 2 log reduction at 12 weeks a total of 72 weeks can be authorized if viral load is undetectable at 24 weeks
  • For Genotype 2/3: approve for 24 weeks**

**Literature states that 24 weeks is adequate to see a sustained virological response in Genotype 2/3 patients.

  • Triple therapy for genotype 1only: peg-interferon + ribavirin+ boceprevir/telaprevir
  • Boceprevir is WHA’s preferred agent for triple therapy

Monotherapy:

Approve for 48 weeks

Monotherapy (PEG-Intron)

Body Wt. (kg) PEG Intron Strength PEG Intron (ug) PEG Intron (ml)
<40 50 ug/0.5 ml 50 0.5
40-50 60 ug/0.5 ml 64 0.4
51-60 60 ug/0.5 ml 80 0.5
61-75 120 ug/0.5 ml 120 0.4
76-85 120 ug/0.5 ml 120 0.5
>85 150 ug/0.5 ml 150 0.5

 

Combination therapy (PEG Intron + Ribavirin)

Body Wt. (kg) PEG Intron Strength PEG Intron (ug) PEG Intron (ml)
<45 50 ug/0.5 ml 40 0.4
40-50 50 ug/0.5 ml 50 0.5

57-72

80 ug/0.5 ml 64

0.4

73-88 80 ug/0.5 ml 80 0.5
89-106 120 ug/0.5 ml 96 0.4
107-136 120 ug/0.5 ml 120 0.5

Other indications should be evaluated on a case-by-case basis

Peginterferon alfa-2A (Pegasys)

JCODE: J3490

Home health administration or self administration 

**oral ribavirin is covered under the Outpatient Benefit

All of the following must be met:

  • Diagnosis of Chronic Hepatitis C
  • Persistently elevated LFT’s (> 6 months)
  • Positive HCV RNA titer
  • Obtain Genotype (1 or 2 or 3)
Approve for combination therapy (Pegasys + ribavirin) *
  • Peg Intron/Intron A Naïve: No history of interferon alfa treatment
  • Intron A Relapser: Prior treatment with Intron A for 6 months with 3 MU TIW and pt. has a complete biochemical remission and then a relapse
  • Intron A Non-Responders: ALT remains abnormal & serum HCV RNA remains detectable after 3 months of Intron A therapy

Pegasys + Ribavirin Relapsers (if completed course of therapy)

  • Allow another full course of Pegasys + Ribavirin

 *Highest response rates seen with combination therapy in Hepatitis C Patients

Patients for whom Pegasys therapy is not indicated include:

  • Patients who do not have persistently elevated LFT’s (> 6 months)
  • Patients with decompensated cirrhosis (ascites, GI bleed, encephalopathy)
  • Patients w/o significant inflammation or fibrosis on liver biopsy (if biopsy available)
  • Hepatitis C Prophylaxis Post- Liver Transplant
  • Patients who have a documented relapse of Hepatitis C post-transplant may be eligible for treatment for up to one year in duration. Refer PA requests to Medical Director.
  • Other Viral Conditions: Acute Hepatitis B or C, Epstein-Barr Virus, Cytomegalovirus
Hepatitis D or E
  • Ribavirin Dosing higher than 1.200 mg per day

PEGASYS/PEGINTRON + RIBAVIRIN NONRESPONDERS

  • If completed course of therapy and no response is seen: Needs medical director review. There is no literature to support continued use of combination therapy in non-responders

Dosing:

Administer 180 mcg SQ once weekly. The dose should be given on the same day of each week

Dose Reduction with Pegasys:

  • ANC < 750 cells/mm3: dose to 135 mcg
  • ANC < 500 cells/mm3: Stop treatment and restart 90 mcg when ANC > 1000 cells/mm3
  • Platelet count < 50,000 cells/mm3: 90 mcg dose
  • Platelet count< 25000 cell/mm3: D/C Pegasys
  • ESRD requiring dialysis: 135 mcg weekly
  • Progressive increases in ALT: 90 mcg weekly
  • ALT levels increase with increased bilirubin, despite dose reduction: D/C therapy STAT
  • Hepatic decompensation: D/C therapy STAT
  • Mod-Severe adverse reactions: dose to 135 mcg or 90 mcg or 45 mcg (depending on severity) and dose when adverse reactions improve. Western Health Advantage Pharmacy and Therapeutics Committee Approved: 5/25/2004

?In anemia associated with Pegasys/Ribavirin Therapy

  • Erythropoietin 40,000 U once weekly

Dose Reduction with Ribavirin without cardiovascular disease and Hgb <10g/dL or stable CV disease with in Hgb by more than 2g/dL during any 4 weeks of T

  • Treatment: dose of ribavirin to 200 mg QAM and 400 mg QPM

W/O cardiovascular disease and Hgb <8.5g/dL or stable CV disease with Hgb value < 12g/dL despite reduced ribavirin dosages for 4 weeks

  • D/C treatment of ribavirin. Restart at 600 mg/day and increase to 800 mg/day based on physician judgment

Monitor:

  • Baseline Labs: CBC, LFTs, HCV RNA PCR
  • Ongoing: CBC, LFTS, HCV RNA PCR q month

Oral Ribavirin Dosing:

  • Approve ribavirin dose of 1000 mg for patients < 75 kg
  • Approve ribavirin dose of 1200 mg for patients > 75 kg

This coverage position on ribavirin dosing is based on the opinions of regional hepatology experts, the VA Guidelines on the diagnosis and treatment of Hepatitis C: OCT 2001, and on the  recommendation of the Western Health Advantage P & T Committee

Pegasys + ribavirin:

Assess whether patient is genotype 1 or genotype 2 or 3

  • Genotype 1 , 4, 6, 7 or any genotype and HIV co-infection: Approve for 12 weeks and obtain viral load to assess response (2 log10 drop or negative HCV RNA) Approve for 36 ADDITIONAL weeks once response is documented
  • In Genotype 1 and 4 patients with no response at 12 weeks, medical director will discuss discontinuing therapy
  • Genotype 1, 4, 6, 7 or any genotype and HIV co-infection with a detectable viral load and a 2 log
  • reduction at 12 weeks a total of 72 weeks can be authorized if viral load is undetectable at 24 weeks
  • For Genotype 2/3: approve for 24 weeks**

**Literature states that 24 weeks is adequate to see a sustained virological response in Genotype 2/3 patients

Monotherapy:

Approve for 48 weeks


 

 

Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.